StockData
Tenax Therapeutics, Inc. logo

Tenax Therapeutics, Inc. (TENX) stock

TENXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$1.42−0.06 (-4.05%)

Close on Nov 17, 2026Market cap $53.14MP/E –Yield –

Tenax Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Tenax Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $45.26M, up 132.0% year over year. For fiscal 2025 it was $32.67M, up 157.1% from the year before. Over ten years it grew 27.0% a year on average. The highest annual figure on record is $32.67M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$32.67M+157.1%
FY2024Dec 31, 2024$12.71M+293.6%
FY2023Dec 31, 2023$3.23M-40.0%
FY2022Dec 31, 2022$5.38M-78.6%
FY2021Dec 31, 2021$25.15M+451.4%
FY2020Dec 31, 2020$4.56M+31.4%
FY2019Dec 31, 2019$3.47M+180.1%
FY2018Dec 31, 2018$1.24M-64.9%
FY2017Dec 31, 2017$3.53M-47.0%
FY2015Apr 30, 2015$6.66M+122.3%
FY2014Apr 30, 2014$3.00M+22.0%
FY2013Apr 30, 2013$2.46M-0.3%
FY2012Apr 30, 2012$2.46M-8.2%
FY2011Apr 30, 2011$2.68M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q2 FY2026CQ2 2026Jun 30, 2026$12.85M+109.9%
Q1 FY2026CQ1 2026Mar 31, 2026$11.54M+103.0%
Q4 FY2025CQ4 2025Dec 31, 2025$10.54M+129.4%
Q3 FY2025CQ3 2025Sep 30, 2025$10.33M+231.9%
Q2 FY2025CQ2 2025Jun 30, 2025$6.12M+163.0%
Q1 FY2025CQ1 2025Mar 31, 2025$5.68M+112.4%
Q4 FY2024CQ4 2024Dec 31, 2024$4.59M+170.3%
Q3 FY2024CQ3 2024Sep 30, 2024$3.11M+192.0%
Q2 FY2024CQ2 2024Jun 30, 2024$2.33M+1075.8%
Q1 FY2024CQ1 2024Mar 31, 2024$2.68M+907.0%
Q4 FY2023CQ4 2023Dec 31, 2023$1.70M+49.8%
Q3 FY2023CQ3 2023Sep 30, 2023$1.07M-30.8%
Q2 FY2023CQ2 2023Jun 30, 2023$197.90K-87.0%
Q1 FY2023CQ1 2023Mar 31, 2023$265.74K-77.4%
Q4 FY2022CQ4 2022Dec 31, 2022$1.13M+23.9%
Q3 FY2022CQ3 2022Sep 30, 2022$1.54M+32.5%
Q2 FY2022CQ2 2022Jun 30, 2022$1.52M+119.9%
Q1 FY2022CQ1 2022Mar 31, 2022$1.18M-94.7%
Q4 FY2021CQ4 2021Dec 31, 2021$915.60K+2.8%
Q3 FY2021CQ3 2021Sep 30, 2021$1.16M+10.4%
Q2 FY2021CQ2 2021Jun 30, 2021$693.22K-45.6%
Q1 FY2021CQ1 2021Mar 31, 2021$22.38M–
Q4 FY2020CQ4 2020Dec 31, 2020$890.96K-83.9%
Q3 FY2020CQ3 2020Sep 30, 2020$1.05M–
Q2 FY2020CQ2 2020Jun 30, 2020$1.27M–
Q1 FY2020CQ1 2020Mar 31, 2020-$1.34M–
Q4 FY2019CQ4 2019Dec 31, 2019$5.52M+180.0%
Q3 FY2019CQ3 2019Sep 30, 2019-$916.98K–
Q2 FY2019CQ2 2019Jun 30, 2019-$649.25K–
Q1 FY2019CQ1 2019Mar 31, 2019-$482.77K–
Q4 FY2018CQ4 2018Dec 31, 2018$1.97M-72.1%
Q3 FY2018CQ3 2018Sep 30, 2018-$362.63K–
Q2 FY2018CQ2 2018Jun 30, 2018-$311.15K–
Q1 FY2018CQ1 2018Mar 31, 2018-$58.59K–
Q4 FY2017CQ4 2017Dec 31, 2017$7.06M+269.4%
Q3 FY2017CQ3 2017Sep 30, 2017-$253.97K-120.7%
Q2 FY2017CQ2 2017Jun 30, 2017-$1.22M–
Q1 FY2017CQ1 2017Mar 31, 2017-$2.05M–
Q4 FY2015CQ1 2015Apr 30, 2015$1.91M–
Q3 FY2015CQ4 2014Jan 31, 2015$1.23M–

More Tenax Therapeutics figures

See a number that looks wrong?